SF3B1 gene study in lymphocytic leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial is studying a gene change called SF3B1 in people with acute or chronic lymphocytic leukemia. It aims to learn more about these blood cancers and may help guide treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have acute lymphocytic leukemia (ALL) or chronic lymphocytic leukemia (CLL).
- You cannot have any other type of cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is examining levels of a protein called LEF1 in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Researchers want to see if LEF1 can help predict survival and confirm diagnosis.
This trial looks at people with acute myeloid leukemia (AML) who have a change in a gene called FLT3. It aims to understand how this change affects the disease and how well treatments work.
This study is for adults with B-cell acute lymphoblastic leukemia (ALL) that does not have three specific gene changes (called BCR-ABL1, TCF3-PBX1, and MLL-AF4). The study will look at people who are newly diagnosed or who have had their cancer come back.
This trial tests an investigational drug called REGN17235 in people with certain low-risk blood disorders (MDS or CCUS) that have a specific genetic change (SF3B1 mutation). The goal is to see if the drug is safe and tolerable.
This study tests a new drug called FXS0683 to treat certain blood cancers (like lymphomas and leukemias) that haven't responded to standard treatments. Researchers want to find the right dose and see if it helps patients whose cancer has come back or isn't responding to other options.
This study uses whole genome sequencing to analyze your leukemia's DNA. The goal is to find unique genetic changes that may help guide future treatments, though this study does not recommend any specific therapy.
Hear when a new Acute Lymphoblastic Leukemia ALL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.